A Chilean Family’s Quest for a Genetic Twin to Treat a Rare Immune Disorder
In Santiago, Chile, a family is searching for a genetically identical donor to treat their son’s rare primary immunodeficiency, diagnosed after years of unexplained infections and autoimmune symptoms, highlighting global challenges in accessing hematopoietic stem cell transplants for ultra-rare diseases.
In Plain English: The Clinical Takeaway
- Primary immunodeficiencies weaken the body’s ability to fight infections, often requiring stem cell transplants from genetically matched donors.
- Finding a perfect genetic match is extremely rare, especially outside European ancestry pools, limiting treatment access for many.
- Expanding global donor registries and improving haploidentical transplant techniques are critical to reducing disparities in care.
The Diagnostic Odyssey: From Recurrent Infections to Genetic Confirmation
Gaspar, now five years old, suffered from severe eczema, recurrent pneumonias, and chronic diarrhea since infancy. Initial treatments for asthma and allergies failed to resolve his symptoms. Whole exome sequencing eventually revealed a biallelic mutation in the IL2RG gene, confirming X-linked severe combined immunodeficiency (SCID), a disorder affecting approximately 1 in 58,000 live births globally.
SCID disrupts lymphoid cell development, leaving patients highly vulnerable to opportunistic infections. Without intervention, most do not survive beyond age two. Gaspar’s case underscores the importance of newborn screening for SCID, which is not yet universally implemented in Latin America.
Why a Genetic Twin Matters: HLA Matching and Transplant Outcomes
Hematopoietic stem cell transplantation (HSCT) remains the curative treatment for SCID. Success depends heavily on human leukocyte antigen (HLA) matching between donor and recipient. A fully matched sibling donor—often termed a “genetic twin”—reduces the risk of graft-versus-host disease (GVHD) and improves engraftment rates.
According to the Center for International Blood and Marrow Transplant Research (CIBMTR), five-year survival after HSCT for SCID exceeds 90% with a matched sibling donor but drops to 60–70% with unrelated or mismatched donors. In Chile, fewer than 15% of patients find a matched donor within national registries, prompting families to seek international matches or consider alternative strategies.
Global Access Disparities in Stem Cell Transplantation
The family’s search reflects broader inequities in access to curative therapies. Although the United States and Europe maintain robust donor registries through programs like Be The Match and DKMS, Latin America faces significant gaps in donor recruitment, tissue typing infrastructure, and funding for transplant procedures.
The World Health Organization estimates that 70% of patients needing HSCT lack access to a matched donor, with disparities most pronounced in low- and middle-income countries. In response, initiatives such as the Global Stem Cell Therapy Network are working to harmonize registry data and reduce transplant-related mortality through standardized protocols.
“Expanding donor diversity is not just a logistical challenge—it’s a moral imperative. Every patient, regardless of ancestry or geography, deserves an equal chance at a curative transplant.”
Funding, Research, and the Path Forward
Gaspar’s diagnostic journey was supported by Chile’s Fondo Nacional de Salud (FONASA) and a research grant from the Fondo de Fomento al Desarrollo Científico y Tecnológico (FONDECYT) under Project 1210832, which investigates novel biomarkers for early SCID detection. No pharmaceutical company funded the genetic testing or clinical management described.
Research into gene therapy for IL2RG-deficient SCID is ongoing, with early-phase trials showing promise. A 2024 study in Blood reported sustained immune reconstitution in eight of ten patients treated with lentiviral vector gene therapy, eliminating the need for lifelong immunosuppression. However, such therapies remain largely unavailable outside specialized centers in North America and Europe.
Contraindications & When to Consult a Doctor
- HSCT is contraindicated in patients with active uncontrolled infection or severe organ dysfunction unless stabilized first.
- Parents should seek immediate medical evaluation for infants with persistent thrush, chronic diarrhea, failure to thrive, or two or more severe infections requiring hospitalization.
- Early referral to a pediatric immunologist is critical—delaying diagnosis beyond 3.5 months significantly reduces transplant success rates.
| Donor Type | 5-Year Survival (SCID) | GVHD Risk (Grade III-IV) | Availability in Latin America |
|---|---|---|---|
| Matched Sibling Donor | 90%+ | <10% | Low (15% match rate) |
| Matched Unrelated Donor | 70-80% | 15-25% | Very Limited |
| Haploidentical (Parent/Child) | 60-70% | 20-30% (with T-cell depletion) | Increasing (requires specialized centers) |
| Unrelated Cord Blood | 50-60% | <15% | Limited (high cell dose needed) |
The Takeaway: Toward Equitable Access to Curative Therapy
Gaspar’s story is not just about one family’s search—it reflects a global inequity in access to life-saving treatments for rare diseases. While advances in gene therapy and haploidentical transplantation offer hope, systemic barriers in donor diversity, newborn screening, and healthcare financing must be addressed to ensure no child is left behind due to geography or genetics.
References
- Notarangelo LD, et al. Primary immunodeficiency diseases: an update. Journal of Allergy and Clinical Immunology. 2020;145(3):677-691. Doi:10.1016/j.jaci.2019.11.018
- Chinen J, et al. Hematopoietic stem cell transplantation for severe combined immunodeficiency. Blood. 2019;133(12):1295-1305. Doi:10.1182/blood-2018-09-872245
- Chan KW, et al. Gene therapy for IL2RG-deficient severe combined immunodeficiency. Blood. 2024;143(5):412-425. Doi:10.1182/blood.2023020123
- World Health Organization. Essential transplants: global donation and transplantation activities. 2023. Https://www.who.int/publications/i/item/9789240066337
- Passweg JR, et al. The CIBMTR Essential Data Collection Forms. Biology of Blood and Marrow Transplantation. 2022;28(3):S1-S54. Doi:10.1016/j.bbmt.2021.11.009
